Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]

A compound represented by Formula (100) and Formula (100′)

• an enantiomer, diastereomer, tautomer, N-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,
• wherein
• R101 and R102 are independently selected from H, C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, C3-10-cycloalkyl, C3-10-heterocycloalkyl, C1-10-alkylene-C3-10-cycloalkyl, C1-10-alkylene-C3-10-heterocycloalkyl, C1-10-alkylene-(5-membered heteroaryl), C1-10-alkylene-(6-membered aryl), C1-10-alkylene-(6-membered heteroaryl), and SO2—C1-10-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR111, O—C2-6-alkylene-OR111, C1-6-alkyl, halo-C1-6-alkyl, halogen, CO2R111, CONR111R112, CONR111SO2R111, COR111, SOxR111, SO3H, SO2NR111R112, NR111COR111, NR111SO2R111, NR111—CO—NR111R112, NR111—SO2—NR111R112, C3-10-cycloalkyl, O—C3-10-cycloalkyl, C3-10-heterocycloalkyl, O—C3-10-heterocycloalkyl and NR111R112;
• or R101 and R102 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR111, SOxR111, SO3H, NR111SO2R111, SO2NR111R112, C0-6-alkylene-CO2R111, CONR111R112, CONR111SO2R111, COR111, NR111—CO—R111, NR111—CO—NR111R112, NR111—SO2—NR111R112, NR111R112, C1-6-alkyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl, C3-8-cycloalkyl, O—C3-8-cycloalkyl, C3-8-heterocycloalkyl and O—C3-8-heterocycloalkyl,
• wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, C1-3-alkyl, halo-C1-3-alkyl, OH, O—C1-3-alkyl, O-halo-C1-3-alkyl, SO2—C1-3-alkyl, COOH and oxo;
• R103 is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,
• wherein aryl and heteroaryl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, halo-C1-6-alkyl, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, C0-6-alkylene-C3-10-cycloalkyl, C0-6-alkylene-C3-10-heterocycloalkyl, C0-6-alkylene-(5- or 6-membered heteroaryl), C1-6-alkylene-O—R131, C0-6-alkylene-CN, C0-6-alkylene-N(R131)2, O—C3-10-cycloalkyl, O—C1-6-alkylene-O—R131, O—C3-10-heterocycloalkyl, C0-6-alkylene-COOR131, C0-6-alkylene-C(O)R131, C0-6-alkylene-C(O)N(R131)2, C0-6-alkylene-N(R131)C(O)R131, C0-6-alkylene-SO—R131, C0-6-alkylene-SO2—R131, C0-6-alkylene-SO2—N(R131)2, C0-6-alkylene-N(R131)SO2—R131, C0-6-alkylene-SO2—C3-10-heterocycloalkyl and C0-6-alkylene-SO2—C3-10-heterocycloalkyl,
• wherein alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C1-3-alkyl, halo-C1-3-alkyl, OH, oxo, ═N—OR132, O—C1-3-alkyl and O-halo-C1-3-alkyl,
• or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C1-6-alkyl, halo-C1-6-alkyl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, oxo, ═N—OR132, OH, O—C1-6-alkyl and O-halo-C1-6-alkyl;
• R104 is selected from (CR108R109)R140, (C═O)R140, OR140, SOy—R107 and C3-6-cycloalkyl, which is spirocyclic fused with R140,
• wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH3 and CF3;
• R107 is selected from C3-10-cycloalkyl and C3-10-heterocycloalkyl,
• wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, halo-C1-6-alkyl, cycloalkyl and heterocycloalkyl;
• R108 is selected from H, F, C1-3-alkyl, halo-C1-3-alkyl, OH, O—C1-3-alkyl and O-halo-C1-3-alkyl;
• R109 is selected from H, F, C1-3-alkyl and halo-C1-3-alkyl;
• R111 is independently selected from H, C1-6-alkyl, C0-6-alkylene-C3-10-cycloalkyl and C0-6-alkylene-C3-10-heterocycloalkyl,
• wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C1-3-alkyl, halo-C1-3-alkyl, O—C1-3-alkyl, O-halo-C1-3-alkyl, NH2, NH(C1-3-alkyl), N(C1-3-alkyl)2, C3-6-heterocycloalkyl, C3-6-cycloalkyl and SO2—C1-3-alkyl,
• wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH3 and CF3;
• R112 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-6-cycloalkyl;
• R131 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl, C0-6-alkylene-C3-8-cycloalkyl, C0-6-alkylene-C3-8-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cyclolalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, ═N—OR132, C1-3-alkyl, halo-C1-3-alkyl, O—C1-3-alkyl, O-halo-C1-3-alkyl and SO2—C1-3-alkyl;
• and optionally wherein two R131 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of fluoro, OH, oxo, C1-4-alkyl and halo-C1-4-alkyl;
• R132 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-6-cycloalkyl;
• R140 is C3-10-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, halo-C1-6-alkyl, C3-8-cycloalkyl and C3-8-heterocycloalkyl;
• x and y are independently selected from 0, 1 and 2.

A compound represented by Formula (1) or Formula (1′)

• an enantiomer, diastereomer, tautomer, N-oxide, solvate, formulation and pharmaceutically acceptable salt thereof, wherein
• R1 and R2 are independently selected from H, C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, C3-10-cycloalkyl, C3-10-heterocycloalkyl, C1-10-alkylene-C3-10-cycloalkyl, C1-10-alkylene-C3-10-heterocycloalkyl, C1-10-alkylene-(5-membered heteroaryl) and SO2—C1-10-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR11, O—C2-6-alkylene-OR11, C1-6-alkyl, halo-C1-6-alkyl, halogen, CO2R11, CONR11R12, CONR11SO2R11, COR11, SOxR11, SO3H, SO2NR11R12, NR11COR11, NR11SO2R11, NR11—CO—NR11R12, NR11—SO2—NR11R12, C3-10-cycloalkyl, O—C3-10-cycloalkyl, C3-10-heterocycloalkyl, O—C3-10-heterocycloalkyl and NR11R12;
• or R1 and R2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR11, SOxR11, SO3H, NR11SO2R11, SO2NR11R12, C0-6-alkylene-CO2R11, CONR11R12, CONR11SO2R11, COR11, NR11—CO—R11, NR11—CO—NR11R12, NR11—SO2—NR11R12, NR11R12, C1-6-alkyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl, C3-8-cycloalkyl, O—C3-8-cycloalkyl, C3-8-heterocycloalkyl and O—C3-8-heterocycloalkyl,
• wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, C1-3-alkyl, halo-C1-3-alkyl, OH, O—C1-3-alkyl, O-halo-C1-3-alkyl, SO2—C1-3-alkyl, COOH and oxo;
• R3 is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,
• wherein aryl and heteroaryl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, halo-C1-6-alkyl, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, C0-6-alkylene-C3-10-cycloalkyl, C0-6-alkylene-C3-10-heterocycloalkyl, C0-6-alkylene-(5- or 6-membered heteroaryl), C1-6-alkylene-O—R31, C0-6-alkylene-CN, C0-6-alkylene-N(R31)2, C0-6-alkylene-O—C3-10-cycloalkyl, O—C1-6-alkylene-O—R31, C0-6-alkylene-O—C3-10-heterocycloalkyl, C0-6-alkylene-COOR31, C0-6-alkylene-C(O)R31, C0-6-alkylene-C(O)N(R31)2, C0-6-alkylene-N(R31)C(O)R31, C0-6-alkylene-SO—R31, C0-6-alkylene-SO2—R31, C0-6-alkylene-SO2—N(R31)2, C0-6-alkylene-N(R31)SO2—R31, C0-6-alkylene-SO2—C3-10-heterocycloalkyl and C0-6-alkylene-SO2—C3-10-heterocycloalkyl,
• wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C1-3-alkyl, halo-C1-3-alkyl, OH, oxo, ═N—OR32, O—C1-6-alkyl, O-halo-C1-3-alkyl, N(R31)2, COOH, CON(R31)2, NR31—COR31, C3-10-cycloalkyl, C3-10-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,
• or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S, N, SO, SO2 or NR31, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C1-6-alkyl, halo-C1-6-alkyl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, oxo, ═N—OR32, OH, O—C1-6-alkyl and O-halo-C1-6-alkyl;
• R4 is selected from (CR8R9)R40, (C═O)R40, OR40, NR41R40, SOy—R7 and C3-6-cycloalkyl, which is spirocyclic fused with R40,
• wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH3 and CF3;
• R7 is selected from C3-10-cycloalkyl and C3-10-heterocycloalkyl,
• wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, halo-C1-6-alkyl, cycloalkyl and heterocycloalkyl;
• R8 and R9 are independently selected from H, F, C1-3-alkyl, halo-C1-3-alkyl, OH, O—C1-3-alkyl and O-halo-C1-3-alkyl;
• R11 is independently selected from H, C1-6-alkyl, C0-6-alkylene-C3-10-cycloalkyl and C0-6-alkylene-C3-10-heterocycloalkyl,
• wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C1-3-alkyl, halo-C1-3-alkyl, O—C1-3-alkyl, O-halo-C1-3-alkyl, NH2, NH(C1-3-alkyl), N(C1-3-alkyl)2, C3-6-heterocycloalkyl, C3-6-cycloalkyl and SO2—C1-3-alkyl,
• wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH3 and CF3;
• R12 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-6-cycloalkyl;
• R31 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl, C0-6-alkylene-C3-8-cycloalkyl, C0-6-alkylene-C3-8-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cyclolalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, ═N—OR32, C1-3-alkyl, halo-C1-3-alkyl, O—C1-3-alkyl, O-halo-C1-3-alkyl and SO2—C1-3-alkyl;
• and optionally wherein two R31 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of fluoro, OH, oxo, C1-4-alkyl and halo-C1-4-alkyl;
• R32 is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-6-cycloalkyl;
• R40 is C3-10-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, halo-C1-6-alkyl, C3-8-cycloalkyl and C3-8-heterocycloalkyl;
• R41 is selected from H, C1-6-alkyl, C3-6-cycloalkyl and C3-6-heterocycloalkyl,
• wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O—C1-6-alkyl, O-halo-C1-6-alkyl, C3-6-heterocycloalkyl and C3-6-cycloalkyl;
• x and y are independently selected from 0, 1 and 2;
• W is selected from C or S═O;
• with the proviso that for R3 the 5-14 membered mono-, bi- or tricyclic heteroaryl containing ring is not
• or a 5-membered aromatic heterocyclic group containing at least one oxygen atom.

A compound according to Formula (2) or Formula (2′)

• an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,
• wherein
• Q1 is selected from CO—NR51R52, CO—R52, CO2R51, SO2—NR51R52, SO2—R52, NR52CO—R51 and NR52SO2—R51;
• Q2 is selected from —O—, —S—, —CR55═CR56—, —N═CR56—, —CR55═N— and —N═N—;
• Q3 is selected from N and CR55;
• R51 and R52 are independently selected from H, C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, C0-10-alkylene-C3-10-cycloalkyl, C0-10-alkylene-C3-10-heterocycloalkyl, C0-10-alkylene-heteroaryl and C0-10-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR61, O—C2-6-alkylene-OR61, C1-6-alkyl, halo-C1-6-alkyl, halogen, CO2R61, CONR61R62, CONR61SO2R62, COR61, SOxR61, SO3H, SO2NR61R62, NR61COR61, NR61SO2R61, NR61—CO—NR61R62, NR61—SO2—NR61R62, C3-6-cycloalkyl, O—C3-6-cycloalkyl, C3-6-heterocycloalkyl, O—C3-6-heterocycloalkyl and NR61R62;
• or R51 and R52 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR61, SOxR61, SO3H, NR61SO2R61, SO2NR61R62, CO2R61, CONR61R62, CONR61SO2R62, COR61, NR61— CO—R61, NR61—CO—NR61R62, NR61—SO2—NR61R62, NR61R62, C1-6-alkyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl, C3-6-cycloalkyl, O—C3-6-cycloalkyl, C3-6-heterocycloalkyl and O—C3-6-heterocycloalkyl;
• R53 is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,
• wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, halo-C1-6-alkyl, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, C0-6-alkylene-C3-10-cycloalkyl, C0-6-alkylene-O—C3-10-cycloalkyl, C0-6-alkylene-C3-10-heterocycloalkyl, C0-6-alkylene-COOR81, C0-6-alkylene-C(O)R81, C0-6-alkylene-C(O)N(R81)2, C0-6-alkylene-SO2—N(R81)2, C0-6-alkylene-SO2—R81, C0-6-alkylene-(6-10-membered mono- or bicyclic aryl) and C0-6-alkylene-(6-10-membered mono- or bicyclic heteroaryl),
• wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, halogen, OH, oxo, ═N—OR82, N(R81)2, O—C1-6-alkyl, O-halo-C1-6-alkyl, COOH, CON(R81)2, CN, NR81—COR81, C3-10-cycloalkyl, C3-10-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,
• or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO2 or NR81, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halogen, oxo, ═N—OR82, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, C3-6-cycloalkyl and halo-C1-6-alkyl;
• R54 is selected from C0-6-alkylene-R57, C3-cycloalkyl-R57, O—C0-5-alkylene-R57, NR91—C0-5-alkylene-R57 and SOx—C0-5-alkylene-R57,
• wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, ═N—OR82, N(R81)2, O—C1-6-alkyl, COOH, CON(R81)2, CN, NR81—COR81, C3-6-cycloalkyl and C3-6-heterocycloalkyl;
• R55 and R56 are independently selected from H, halogen, CN, C1-6-alkyl and O—C1-6alkyl,
• wherein alkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-3-alkyl;
• O-halo-C1-3-alkyl and C3-6-cycloalkyl;
• R57 is selected from C1-10-alkyl, C3-10-cycloalkyl, C3-10-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,
• wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O—C1-6-alkyl, O-halo-C1-6-alkyl, C1-6-alkyl, halo-C1-6-alkyl, cycloalkyl and heterocycloalkyl;
• R61 and R81 independently selected from H, C1-6-alkyl, C3-10-cycloalkyl, C3-10-heterocycloalkyl, phenyl, and 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S
• wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, phenyl, heteroaryl, halogen, NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, C3-10-heterocycloalkyl, C3-10-cycloalkyl, SO2—C1-3-alkyl, oxo and CN,
• wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, phenyl, heteroaryl, halogen, NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2 and C3-10-cycloalkyl,
• wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O—C1-6-alkyl, O-halo-C1-6-alkyl, halogen, C1-6-alkyl, halo-C1-6-alkyl, NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2 and C3-10-cycloalkyl;
• R62 and R82 are independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-10-cycloalkyl;
• R91 is selected from H, C1-6-alkyl, C3-6-cycloalkyl and C3-6-heterocycloalkyl,
• wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O—C1-6-alkyl, O-halo-C1-6-alkyl, C3-6-heterocycloalkyl and C3-6-cycloalkyl;
• x is independently selected from 0, 1 and 2;
• for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor;
• with the proviso that compounds of Formula (2′) with Q1 is NHCO—R51, Q2 is sulfur, Q3 is nitrogen, R53 and R57 are optionally substituted aryl and R54 is COR57 are excluded.